GTC
NTLA icon

Ghost Tree Capital’s Intellia Therapeutics NTLA Stock Holding History

Ghost Tree Capital’s Portfolio NTLA Stock Details NTLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-25,000
Closed -$560K – 68
2024
Q2 		$560K Hold
25,000
– – 0.18% 61
2024
Q1 		$688K Buy
+25,000
New +$694K 0.19% 72
2018
Q1 		– Sell
-175,000
Closed -$3.36M – 61
2017
Q4 		$3.36M Buy
+175,000
New +$4.04M 0.79% 38

Other funds holding NTLA

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Ghost Tree Capital's NTLA Position: Q3 2024 in Review

Ghost Tree Capital sold out of Intellia Therapeutics (NTLA) in Q3 2024, closing a stake of 25,000 shares — an estimated $560K sold.

Ghost Tree Capital first reported a position in NTLA in Q4 2017 and held it in 3 quarters. The position peaked at $3.36M in Q4 2017. 283 funds tracked by Wall St. Rank hold NTLA as of Q3 2024.

  • Ghost Tree Capital reported no remaining Intellia Therapeutics position as of Q3 2024 after selling out during the quarter.
  • Ghost Tree Capital sold 25,000 Intellia Therapeutics shares in Q3 2024, an estimated $560K.
  • Ghost Tree Capital first reported a position in Intellia Therapeutics in Q4 2017 and held it in 3 quarters.
  • Ghost Tree Capital's Intellia Therapeutics position peaked at $3.36M in Q4 2017.
  • 283 funds tracked by Wall St. Rank held Intellia Therapeutics as of Q3 2024.

Based on Ghost Tree Capital's 13F filing for Q3 2024, filed 14 Nov 2024.